GovChime
Notice ID: d56569b1c2394da79f36e26c8fc4ddc4Award NoticeAwarded

Long-Acting Antiviral Implant for the Treatment of HCV

Awarded on September 1, 2024. Full description on SAM.gov.

Awarded tounder 75N93024C00028 (source: SAM.gov award notice)• $300.0K

Overview

Posted
September 3, 2024
Notice type
Award Notice
Set-aside
Total Small Business Set-Aside (FAR 19.5)
NAICS
541715: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Agency
Department of Health and Human Services

Notice details

Place of performance
Charlottesville, VA, 50011
Last updated
Dec 4, 2025
Award date
Sep 1, 2024
Award amount (SAM.gov award notice)
$300.0K

Identifiers

Solicitation number
PHS-2024-1
Notice ID
d56569b1c2394da79f36e26c8fc4ddc4
Award number (PIID)
75N93024C00028

Description

Synopsis: The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) are soliciting proposals from small business concerns that possess the research and development (R&D) expertise to conduct innovative research that will contribute toward NIH or CDC mission needs and Small Business Innovation Research (SBIR) program objectives. THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (DHHS), THE NATIONAL INSTITUTES OF HEALTH (NIH), AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) SMALL BUSINESS INNOVATIVE RESEARCH (SBIR) PROGRAM SOLICITATION PHS-2024-1 is anticipated to be made available on or around August 25, 2023, through both SAM.gov and the NIH Small Business Innovation Research (SBIR)/Small Business Technology Transfer (STTR) funding web page at https://sbir.nih.gov/funding. This solicitation is anticipated to have a closing date of November 14, 2023 for receipt of proposals. The purposes of the SBIR program are to: (a) stimulate technological innovation; (b) strengthen the role of small business in meeting Federal research/research & development (R/R&D) needs; (c) foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns; and (d) increase private sector commercialization of innovations derived from Federal R/R&D, thereby increasing competition, productivity and economic growth. For purposes of the SBIR program, a small business concern is any business concern that, on the date of award, (1) is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor; (2) is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture; (3) more than 50% directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50% directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these; OR more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50% of the concern; AND, (4) has, including its affiliates, no more than 500 employees.* * Note: This size standard is established by law for the SBIR program, regardless of the NAICS Code assigned. See 13 C.F.R. § 121.702. THE FOLLOWING RESEARCH TOPICS ARE ANTICIPATED TO BE INCLUDED IN SBIR CONTRACT SOLICITATION PHS-2024-1 NATIONAL INSTITUTES OF HEALTH (NIH) NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS): Topic 024 - Small Manufacturing Systems to Produce Research Grade Pharmaceutical Intermediates NATIONAL CANCER INSTITUTE (NCI): Topic 455 - Point-of-Care Detection of Prostate Specific Antigen Topic 456 - Rapid and Affordable Point-of-Care HPV Diagnostics for Cervical Cancer Control Topic 457 - Technologies for Detecting Tumor-Derived Cell Clusters Topic 458 - Microbiome-Based Tests for Cancer Research, Diagnosis, Prognosis and/or Patient Management Topic 459 - Automated Software for Point-of-Care Testing to Identify Cancer-Associated Malnutrition Topic 460 - Evaluation Datasets as Medical Device Development Tools for Testing Cancer Technologies Topic 461 - Ultra-Fast Dose Rate (FLASH) Radiation Detectors and Safety Systems for Cancer Treatment Topic 462 - Organ-on-Chip for Preclinical and Translational Radiobiological Studies Topic 463 - Translation of Novel Cancer-specific Imaging Agents and Techniques to Mediate Successful Image-guided Cancer Interventions Topic 464 - Cloud-Based Multimodal Data Analysis Software for the Cancer Research Data Commons Topic 465 - Cancer Prevention and Treatment Clinical Trials Tools for Recruitment and Retention of Diverse Populations NATIONAL INSTITUTE ON AGING (NIA): Topic 010 - Technology to facilitate characterization of the exposome in under –resourced populations for AD/ADRD Studies NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID): Topic 124 - Development of Next-Generation Devices and Materials-Based Platforms for the Administration of HIV-1 Broadly Neutralizing Antibodies Topic 125 - Development of Long-Acting Treatments for HCV Cure Topic 126 - Rapid Diagnostic Assays for Self-Monitoring of Acute or Rebound HIV-1 Infection Topic 127 - Multiplexed Patient Administered Diagnostics for Hepatitis B, Hepatitis C, and HIV Topic 128 - Adjuvant Development for Vaccines for Infectious and Immune-Mediated Diseases Topic 129 - Reagents for Immunologic Analysis of Non-mammalian and Underrepresented Mammalian Models Topic 130 - Adjuvant Discovery and Down-Selection for Vaccines against Infectious and Immune-Mediated Diseases Topic 131 - Development of Bacteriophage for Treatment of Mycobacterial Infections Topic 132 - Novel Diagnostic Biomarker Discovery and Validation for Malaria and Select Neglected Tropical Diseases (NTDs) Topic 133 - Development of a Serological Test for Herpes Simplex Types 1 and 2 Infections Topic 134 - Alternatives to Benzathine Penicillin for Treatment of Syphilis Topic 135 - Software or Web Services to Automate Metadata Enrichment and Standardization for Data on Infectious and Immune – Mediated Diseases Topic 136 - Software or Web Services to Re-Represent Existing Scientific Data and Knowledge into a Knowledge Graph Format NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI): Topic 115 - Clinical Instrument for Para-Hydrogen (pH2) Based Signal Amplification by Reversible Exchange (SABRE) for Hyperpolarizing 13C-Pyruvate and Other Probes for MRI Imaging NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH): Topic 001 - Point-of-Care HIV Viral Load and Drug Adherence Assays Topic 002 - Development of novel In-vitro and In-vivo Models to support NeuroHIV Research CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) NATIONAL CENTER FOR EMERGING ZOONOTIC AND INFECTIOUS DISEASE (NCEZID): Topic 03 - Development of SHERLOCK Assay for Detection of High Threat Orthopoxviruses NATIONAL CENTER FOR HIV/AIDS, VIRAL HEPATITIS, STD, AND TB PREVENTION (NCHHSTP): Topic 055 - Software Solutions: Bridging the Gap between Public Health and Pharmacies Topic 056 - EHR Algorithm to Identify Persons with HIV Not in Care Topic 057 - Device for point-of-care nucleic acid purification and detection of HCV NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES (NCIRD): Topic 036 - Improved Diagnostic Assays for Measles, Mumps, Rubella, and Varicella Topic 037 - Rapid Diagnostic Tests for Measles, Mumps, Rubella, and Varicella NOTE – SBIR / STTR GRANT OPPORTUNITIES SBIR and STTR grant opportunities are also available for investigator-initiated ideas. Companies are encouraged to review omnibus SBIR/STTR grant solicitations of the National Institutes of Health, Centers for Disease Control and Prevention and Food and Drug Administration posted on the NIH SBIR/STTR funding web page located at https://sbir.nih.gov/funding#omni-sbir. Standard due dates for SBIR/STTR grant applications are September 5th, January 5th, and April 5th. To understand better the differences between grants and contracts, see https://sbir.nih.gov/apply. For general information regarding the NIH/CDC SBIR Program, please refer to: Office of Extramural Programs, Office of Extramural Research National Institutes of Health Phone 301-435-2688 seedinfo@nih.gov

Full description on SAM.gov

Award Overview

Award Number

75N93024C00028

Award Amount (SAM.gov award notice)

$300.0K

Award Date

Sep 1, 2024

Awardee

Awardee UEI

M6JVSYRQRYM9

Original Solicitation

Notice ID: d56569b1c2394da79f36e26c8fc4ddc4

Posted Date: Sep 3, 2024

Original Response Deadline: Not specified

More From This Vendor

Top 5 most recent

3
  • 75N93023C00037
    LUNA LABS USA LLC
    Department of Health and Human ServicesNAICS 541715
    $600.0KSigned Aug 20, 2025
  • 75N93024C00041
    LUNA LABS USA LLC
    Department of Health and Human ServicesNAICS 541715
    $300.0KSigned Jun 25, 2025
  • 75N93024C00041
    LUNA LABS USA LLC
    Department of Health and Human ServicesNAICS 541715
    $300.0KSigned Apr 14, 2025

Contacts

Documents

No documents available.

Lifecycle

Solicitation:PHS-2024-1
  1. Awarded

This opportunity has been awarded.

  1. 10×
    AwardedCurrentAug 1, 2024

    Long-Acting Antiviral Implant for the Treatment of HCV

    Notice d56569b1c2394da79f36e26c8fc4ddc4 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
Opportunity updated November 6, 2026, to attach an Amended Questions and Answers (Q&As) Document that includes all Q&As submitted by the November 3, 2026, deadline. Opportunity updated October 26, 2026, to attach Pre-solicitation Conference Charts and Received to date Questions and Answers. Version 2-The purpose of Draft RFP 80LARC27R0003 Version 2 is to document changes to Provision L.9 1852.215-77 Preproposal/Pre-Bid Conference, to add the date/time and update Registration Details as noted below and in the attached Draft RFP Version 2 dated 10.8.26: L.9 1852.215-77 Preproposal/Pre-Bid Conference A preproposal/pre-bid conference will be held as indicated below: The conference will be unclassified. Date: October 19, 2026 Time: 1:00 to 3:00 PM Eastern Time Location: NASA Langley Research Center (LaRC) Virtual conference Other Information, as applicable: Registration Details: Prospective vendors shall register via email no later than October 16, 2026 at 12:00 PM Eastern Standard Time in advance of the conference by sending an email with a list of all planned attendees to Lindsey Leso at larc-easss@mail.nasa.gov. The Contract Specialist will send an email invite to each participant no later than the day of the conference. Prospective vendors are advised to frequently monitor the https://sam.gov web site for any changes to the date or time of the conference, including other changes to the solicitation. Prospective vendors are requested to submit any written questions to Lindsey Leso via email at larc-easss@mail.nasa.gov no later than TBD so that NASA can answer as many questions as possible at the conference. Questions, responses, conference attendees, and conference materials presented at the conference will be transmitted/communicated by amendment to the solicitation on sam.gov. Attendance at the preproposal/pre-bid conference is recommended; however, attendance is neither required nor a prerequisite for proposal/bid submission and will not be considered in the evaluation. The Government will respond to questions regarding this procurement provided such questions have been received at least five (5) working days prior to the conference. Other questions will be answered at the conference or in writing at a later time. All questions, together with the Government's response, will be transmitted to all solicitation recipients via the government-wide point of entry (GPE). In addition, conference materials distributed at the preproposal/pre-bid conference will be made available to all potential offerors via the GPE. (End of provision) You are invited to review and comment on the National Aeronautics and Space Administration (NASA) Langley Research Center (LaRC)’s EASS draft solicitation. The principal purpose of this requirement is to acquire support services for the Science Office for Mission Assessments (SOMA), located at NASA Langley Research Center. SOMA is responsible for the management and oversight of evaluations, assessments, analyses, and other support services for the NASA Headquarters Science Mission Directorate (SMD). The scope includes proposal/Phase A reports; evaluations for SMD Announcements of Opportunity (AO) flight investigations; assessments for independent reviews of investigations and programs; analyses related to assessment and evaluations; and other contractor support services as specified in individual TOs. The EASS procurement is essential for the advancement of the NASA Science Plan, A Vision for Scientific Excellence. This contract directly supports SOMA and SMD. The contractor ensures that all work is objective and meets all requirements regarding organizational and personal conflicts of interest and limitations of future contracting as defined by this contract and as further defined in individual TOs where necessary. This contract supports NASA’s most urgent and important science needs, and without this contract, SMD would be unable to execute its extensive scientific commitments and achieve NASA’s science priorities. See attached Draft RFP Cover Letter and attachments for full details.
-Pre-Solicitation11/03/2026
This is a SMALL BUSINESS SOURCES SOUGHT NOTICE. This is NOT a solicitation for proposals, proposal of abstracts or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses (e.g., 8(a), Veteran-owned small businesses, service-disabled Veteran-owned small businesses, HUBZone small businesses, small disadvantaged businesses, and women-owned small businesses); (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition; and (4) whether commercials sources and services are available in the marketplace. Your response to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code 541715 should not submit a response to this notice. This notice is issued to help determine the appropriate acquisition method including small business socioeconomic set aside possibilities and to determine the availability of commercial or non-commercial companies technically capable of meeting the Government's potential requirement. It is not construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Furthermore, it should be noted that any future solicitations that may be issued as a result of this notice, or in response to this requirement, may be issued using a different solicitation number from the one identified above. The National Institute on Drug Abuse (NIDA) Division of Therapeutics and Medical Consequences (DTMC) and National Institutes of Health (NIH) is seeking Capability Statements from Small Business organizations with the demonstrated capability of providing service to support NIDA DTMC with the synthesis and distribution of drugs of abuse and related compounds. BACKGROUND AND OBJECTIVES: The National Institute on Drug Abuse (NIDA) is seeking capability statements from small businesses with the capability to synthesize and distribute drugs of abuse and related compounds. The NIDA Drug Supply Program has played an important role in promoting and supporting the substance use research by providing a wide variety of authentic, pure, controlled and uncontrolled drugs and other chemical compounds (both unlabeled and labeled with deuterium, tritium, carbon -14, and iodine-125 isotopes) to the drug abuse research community for basic research. To continue to supply authentic and pure drugs and research chemicals, NIDA maintains the drug supply inventory, periodically check chemical purity and supply to research investigators according to the NIDA drug supply guidelines. Specifically, NIDA plans to continue to: (1) produce, acquire, synthesize and maintain several radio and deuterium labeled and unlabeled drugs of abuse and other chemical substances in its drug supply inventory and distribute them to research investigators upon approval; (2) analyze, test, establish, and maintain the purity of drugs of abuse, and other chemical compounds in the NIDA drug supply inventory and produce updated chemical data sheets; (3) to replenish existing drug supply inventory with depleted drugs and research compounds with the synthesis or acquisition of depleted drug/chemical substances routinely; (4) to identify, acquire, and update the drug supply inventory with newly discovered chemical compounds useful for drug abuse research; (5) to use, maintain, and update the NIDA drug supply data base, known as Drug Inventory Supply Control System (DISCS); and (6) accept and process request packages from researchers; (7) Provide secure storage for all compounds and safe shipment of approved drugs/compounds to research investigators. Capable vendors must demonstrate the capability to receive the current inventory of hundreds of DEA controlled and uncontrolled drugs, other chemical compounds including peptides (opioid and related neuropeptides) in several kilogram quantities for immediate storage. Many of these compounds will require refrigeration. Some substances are in solution form and therefore require appropriate and secure storage to meet DEA requirements. Chemical compounds to be synthesized shall include new drugs, drug metabolites and other compounds as directed by NIDA. Specific compounds may include but not be limited to unlabeled compounds as well as compounds labeled with tritium, 125I, 14C, and deuterium and 13C. Representative classes of compounds shall include cannabinoids, hallucinogens, narcotics and antagonists, stimulants, depressants, peptides (opioid and related neuropeptides). All chemical compounds must be stored under optimum shelf‑life conditions and their purity maintained at not less than 95%. Re-purification must be carried out if chemical or radiochemical deterioration occurs. MANDATORY REQUIREMENTS: To handle controlled substances under the Controlled Substances Act of 1970, it is mandatory that the successful capable vendors possess a DEA Research Registration for Schedules II to V and demonstrate the capability to obtain a DEA registration for Schedule I controlled substances. INSTRUCTIONS: Based on preliminary market research, the Government has determined that the requirements described herein do not meet the definition of a commercial product or commercial service as defined in RFO 2.101, and therefore, RFO Part 12 procedures are not applicable to this requirement. However, if a capable vendor believes that these services or products qualify as commercial under FAR 2.101, the vendor may submit a written justification for the Contracting Officer's consideration. Such submissions must be provided to the Contracting Officer no later than November 20, 2026 at 1:00 PM EST. Respondents must provide clear and convincing documentation of their capability and experience with providing the personnel and services as specified in the tasks above. Also, information must be provided in sufficient details of the respondents’ (a) staff expertise, including their availability, experience, formal and other training; (b) current capability to perform the work; (c) prior completed projects of similar nature; (d) corporate experience and other management capability; and (e) examples of prior completed Government contracts, references, and other related information. Each capability statement must include the respondent’s UEI number, organization name, and address. Each response should include the technical and administrative points of contact with, names, titles, addresses, telephone numbers, and e-mail addresses. The capability statement should clearly identify the size and type of business (e.g., 8(a), HubZone, Non-Profit, Other Than Small Business, etc.), pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2” x 11” paper size, with 1” top, bottom, left and right margins, and with single or double spacing. The information submitted must be in an outline format that addresses each of the elements of the project requirement and in the capability statement paragraphs stated herein. A cover page and an executive summary may be included but is not required. The response is limited to ten (10) pages. The 10-page limit does not include the cover page, executive summary, resumes, or references, if requested. Any business concerns that believe they possess the capability necessary to successfully undertake the work described above must SUBMIT CAPABILITY STATEMENTS ELECTRONICALLY to the Contract Specialist, Shaun Rostad at Shaun.Rostad@nih.gov, NO LATER THAN 1:00 p.m. EST on November 20, 2026. The Subject line for the submission should include this Sources Sought Number, SAM.gov Unique Entity Identifier (UEI) and organization name. NIDA will not accept paper or faxed capability statements. THIS NOTICE IS NOT A REQUEST FOR PROPOSALS. This notice is for information and planning purposes only and does not commit the Government to any contractual agreement. This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in SAM.gov. However, responses to this notice will not be considered adequate responses to a solicitation. CONFIDENTIALITY. No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).
-Market Research11/20/2026
The Advanced Research Projects Agency for Health (ARPA-H) is soliciting proposals from small business concerns (SBCs) that possess the research and development (R&D) expertise to conduct innovative research that will contribute toward ARPA-H mission needs, Small Business Innovation Research (SBIR), and Small Business Technology Transfer (STTR) program objectives. Please see the cover page of the attachment "SBIR_STTR_BAA_FY26" for applicable Stage 1 and Stage 2 deadlines for each open topic. Please see the Attachment H "ARPA-H_SBP_Government_Answered_Questions" for responses to the Q&A period. The purposes of the SBIR and STTR programs are to: (a) stimulate technological innovation; (b) strengthen the role of small business in meeting Federal research/research & development (R/R&D) needs; (c) foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns; and (d) increase private sector commercialization of innovations derived from Federal R/R&D, thereby increasing competition, productivity and economic growth. For purposes of the SBIR and STTR programs, a small business concern is any business concern that, on the date of award, (1) is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor; (2) is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture; (3) more than 50% directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50% directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these; OR more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50% of the concern; AND, (4) has, including its affiliates, no more than 500 employees. Note: This size standard is established by law for the SBIR program, regardless of the NAICS Code assigned. See 13 C.F.R. § 121.702. AMENDMENT 01 - July 8, 2026: Amendment 01 of this solicitation extends the deadline for Stage 1 Solution Summaries from July 10, 2026 to July 17, 2026. This amendment answers conforming questions that were submitted prior to the Q&A deadline via Attachment H. This amendment adds/revises the following soliciation sections: Add change log, revise sections 2.3, 3.1, 3.2, 4.2, 4.3, 4.4, 5.0, 5.4, add section 5.5, revise section 8, topic 6, and topic 7. AMENDMENT 02 - August 17, 2026: Amendment 02 of this solicitation publishes the Stage 2 submission deadline for Topics 01, 02, 03, 04, 06, and 07. This amendment revises language in the following sections: cover page, 2.2, 2.3, 2.4, 2.6, 2.8, and 8. Amendment 02 corresponds with Stage 1 encourage/discourage letter distribution for topics 01, 02, 03, 04, 06, and 07. Please check your email inbox for your Stage 1 encourage/discourage letters on or around August 17, 2026. Topic 05 Stage 1 letters and Stage 2 submission deadline will be distributed at a later date. AMENDMENT 03 - September 1, 2026: Amendment 03 of this solicitation publishes the Stage 2 submission deadline for Topic 05. This amendment revises language in the following sections: cover page and 8. Amendment 03 corresponds with Stage 1 encourage/discourage letter distribution for topic 05. Please check your email inbox for your Stage 1 encourage/discourage letters on or around September 1, 2026. Amendment 03 updates Attachment B Cost Proposal Spreadsheet Template. AMENDMENT 04 - September 10 2026: Amendment 04 of this solicitation revises the Stage 2 submission deadline for Topics 01, 02, 03, 04, 06, and 07. This amendment revises language in the following section: cover page and 8. This amendment updates Attachment B Cost Proposal Spreadsheet Template. AMENDMENT 05 - September 11 2026: Amendment 05 of this solicitation revises the Stage 2 submission deadline for Topics 01, 02, 03, 04, 06, and 07. This amendment revises language in the following section: cover page and 8. This amendment updates Attachment B Cost Proposal Spreadsheet Template. This amendment also unprotects Attachment B Cost Proposal Spreadsheet and updates the instructions sheet. THE FOLLOWING ARE THE CURRENTLY OPEN RESEARCH TOPICS. PLEASE SEE SECTION 8 OF THE BAA FOR FURTHER INFORMATION ARPA-H 01 - Development of an annual test to inform women about their future fertility - The purpose of this topic is to discover new biomarkers that provide women with actionable data for fertility planning. Results from this work will help inform the program manager regarding the feasibility of future programs focused on enhancing natural fertility before the need of IVF and guiding the development of women’s health monitoring and improvement tools. This work will develop a diagnostic test that can assess fertility status and generate an estimated timeline for the onset of infertility. This topic seeks to develop a test that is affordable, suitable for at least annual use, and provides user-friendly results for patients and care teams to support childbearing decisions. ARPA-H 02 - Versatile Bioadhesives - The purpose of this topic is to develop next-generation bioadhesive platforms that can safely and reliably seal, bond, and repair a wide range of tissues in challenging clinical conditions, including wet, bloody, and mechanically dynamic environments. These platforms may also be designed to deliver biologics or small molecules as part of treatment. The goal is to create bioadhesives with key performance attributes such as strong tissue adhesion, controlled degradation, reversibility, biocompatibility, and broad compatibility across multiple tissues and organs. If successful, this topic could enable widely deployable solutions for hemostasis, leak prevention, tissue repair, and device fixation, ultimately helping reduce complications and improve patient outcomes across many care settings ARPA-H 03 - Universal Platform for Living Adaptive Toxin-removal (UNI-PLAT) - The purpose of this topic area is to catalyze the development of a universal, “plug-and-play” synthetic biology platform that enables next-generation microbial chassis capable of performing a broad array of programmable functions. While this solicitation primarily uses toxin removal as a proof-of-concept in relation to chronic disease management, the platform is intended to be adaptable to a range of challenges across industries such as environmental remediation, biomanufacturing, agriculture, holistic medicine, and therapeutic discovery. The broader goal is to create a stable, reliable, and easily reprogrammable microbial platform that demonstrates potential for cross-sector impact beyond the initial use case. ARPA-H 04 - Breaking Ground: The First Curative, Durable, Non-Surgical Therapy for Endometriosis – The purpose of this topic aims to develop treatments for endometriosis that are non-surgical. Proposers are expected to develop novel, non-surgical therapies to decrease the size or deactivate endometrial implants, to decrease inflammation cause by implants, and / or prevent growth or regrowth of the lesions. Broadly, this should be a novel, non-surgical, curative treatment for endometriosis. ARPA-H 05 - ARPA-H Lineage Topic - The purpose of this topic supports the advancement, commercialization, and translation of technologies that originated from ARPA-H funded efforts. It is intended to help small businesses and startups develop viable products based on these technologies. ARPA-H’s goal is to give small businesses an off-ramp to finish developing their technology/product, explore secondary or interim applications of the technology, and time to achieve self-sufficiency. ARPA-H 06 - Rapid Comprehensive Diagnostic Test for Multi-System Autoimmune Disease -The purpose of this topic is to spur the development of novel, rapid diagnostic assays for multi-system autoimmune disease, which represents an unmet healthcare need. Moreover, in its ideal embodiment this diagnostic test might allow typical primary care physicians to diagnose and predict tissue-specific autoimmune disease manifestations, thereby streamlining referral of the patient to a specialist. This goal is made more feasible by recent technological developments including the ability to detect tissue-specific signatures of immune-mediated stress by assessing circulating cells and/or tissue-specific molecular products. ARPA-H 07 - Virtual Human Brain for the Development of Neurosurgical Robotics - The purpose of this topic aims to take a first step toward AI-assisted intracranial microsurgery by creating a high-resolution, physically and anatomically accurate virtual human brain.
-Pre-Solicitation10/01/2026
Randomized Controlled Trial of a Novel Clinical Decision Support Tool for Individualized Exercise Recommendations in Breast Cancer Survivors.
-Pre-Solicitation11/25/2026
This is a Small Business Sources Sought (SBSS) Notice for Research and Development (R&D). This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of qualified small businesses under the size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. The anticipated North American Industry Classification System (NAICS) code is 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology), and the small business size standard for such requirements is 1,000 employees or less, including applicable affiliates. This SBSS notice is for market research and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the Government. The purpose of this synopsis is to identify small business organizations with requisite qualifications to provide the services stated herein. Based on capability statements received in response to this Sources Sought Announcement, this acquisition may be solicited as a small business set-aside. All small business organizations (SB, SDB, WOSB, HUBZone, VOSB, and SDVOSB) are encouraged to respond to this notice. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice.
-Market Research11/23/2026

Additional Details

Solicitation Number

PHS-2024-1

Archive Date

Sep 16, 2024

Office Address

BETHESDA, MD, 20892